#$PCVX
$PCVX NEWS Nov 13: VAX-31 Phase 3 study with flu vaccine marked completed. The co-administration study in 1,390 adults aged 50 and older completed on Oct 21, 2026; results are not yet posted.

Full story (not investment advice): https://www.merlintrader.com/vaxcyte-stock-hub/
November 16, 2026 at 2:13 PM
$83K traded in #$PCVX options, split $56K calls / $26K puts (68% calls).
Off-exchange trading by session (share of volume): Nov 13 209,217 (33.6%).
The dark pool ratio Nov 13 was 0.2x normal and the 5-day trend is fading.

Full story at the link.
#optionsflow #stocks #optionstrading #stockmarket
Vaxcyte (PCVX) Technical Levels: Options Flow, Dark Pools Line Up Above $62.24
PCVX at $63.37: support $62.24, resistance $68.92; the chart, options flow and dark pools line up bullish.
globaltradersacademy.com
November 14, 2026 at 9:29 AM
#$PCVX: Dark pool prints by session, % of volume in brackets: Nov 11 542,013 (33.4%).
$30K traded in #$PCVX options, split $29K calls / $1,912 puts (94% calls).
Nov 11: dark pool volume 0.6x normal, trending fading across 5 sessions.

Full story at the link.
#darkpool #stocks #stockmarket
Vaxcyte (PCVX) Technical Levels: Options Flow, Dark Pools Line Up Above $63.37
PCVX at $68.62: support $63.37, resistance $68.92; the chart, options flow and dark pools line up bullish.
globaltradersacademy.com
November 12, 2026 at 2:09 PM
November 9, 2026 at 4:45 PM
$PCVX: Vaxcyte reported $2.26B of cash at Sept 30, about $3.4B pro forma after ~$1.1B raised in October; Q3 net loss was $297.1M. Not investment advice.

https://www.merlintrader.com/vaxcyte-stock-hub/
November 8, 2026 at 3:50 PM
Vaxcyte ($PCVX) – 13G holder adds

• Holder: T. Rowe Price Investment Management
• Stake: 9.6% → 11.6% (about $1.1B)
• Shares: 14,312,368 → 18,136,166
• Filed: Nov 6 · Schedule 13G/A

📊 More at www.elixstocks.com

Educational only. Not investment advice.

#Investing #Stocks
T. Rowe Price Investment Management, Inc.: 11.6% of Vaxcyte ($PCVX)
Schedule 13G/A filed Nov 6. Who filed, the stake, and how it changed.
elixstocks.com
November 6, 2026 at 5:28 PM
Vaxcyte ($PCVX) – 13G holder update

• Holder: T. Rowe Price Investment Management
• Stake: now 9.6% (about $886M)
• Filed: Nov 6 · Schedule 13G/A

📊 Track ownership filings at www.elixstocks.com

Educational purposes only. Not investment advice.

#Investing #Stocks #13G #ElixStocks
T. Rowe Price Investment Management, Inc.: 9.6% of Vaxcyte ($PCVX)
Schedule 13G/A filed Nov 6. Who filed, the stake, and how it changed.
elixstocks.com
November 6, 2026 at 6:09 PM
Vaxcyte: Q3: cash and investments $2.264B, ~$3.4B pro forma after ~$1.1B October raise; 9M cash use $737.2M.

#$PCVX FAQ + PDF report: www.merlintrader.com/vaxcyte-stoc...
November 5, 2026 at 2:10 PM
🚨 $PCVX
Cowan Elvia (SVP, Finance & CAO) sold 3,000 shares at an average price of $60.9178 per common share. (Date: 2026-11-02)
SEC Filing: PCVX
Click to view the official SEC document.
www.sec.gov
November 4, 2026 at 10:33 PM
Vaxcyte $PCVX reported Q3 2026 EPS of -$1.99, beating the -$2.06 estimate by 3.4%. Revenue was $0. No analyst estimate was published for revenue.

https://fundspec.ai/s/PCVX/earnings
Stress test revenue, margin and WACC to see the real upside and downside.
November 4, 2026 at 9:34 PM
🚨 $PCVX
Wassil Jim (EVP, Chief Scientific Ofc, COO) sold 2,250 shares at an average price of $60.8996 per common share. (Date: 2026-11-02)
SEC Filing: PCVX
Click to view the official SEC document.
www.sec.gov
November 4, 2026 at 10:32 PM
🚨 $PCVX
On November 4, 2026, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.
SEC Filing: PCVX
Click to view the official SEC document.
www.sec.gov
November 4, 2026 at 9:21 PM
🚨 $PCVX
Cowan Elvia, a Officer, filed a notice of intent to sell 3,000 shares of common stock, valued at approximately $185,640.00, on 11/02/2026.
SEC Filing: PCVX
Click to view the official SEC document.
www.sec.gov
November 2, 2026 at 9:12 PM
#$PCVX weekly close $62.03 (+2.6% w/w), above SMA50 $61.60 / above SMA200 $57.04, RSI 48.8. Range $59.19-$90.75.

PCVX Stock Hub: Vaxcyte News, Operations and Capital
www.merlintrader.com/vaxcyte-stoc...
PCVX Stock: Vaxcyte News & Financials
Vaxcyte stock news: The report explains the VAX-31 adult and infant programs, serotype-level comparisons and the limits of topline vaccine…
www.merlintrader.com
November 2, 2026 at 11:24 AM
$PCVX-1 $XLY-1 $DGXX-1 $RSP-1 $PEP-1 $WMT-1 $CVNA-1 $KRE-1 $RKLB-1 $GEN-1 $EBAY-1 $SBLK-1 $BYD-1 $LUNR-1 $ABSI-1 $BOIL-1 $DRAM-1 $CYPH-1 $CXW-1 $NEO-1 $ICLR-1 $AOS-1 $QLD-1 $VMRK-1 $TDOC-1 $IVW-1 $OSPN-1 $GLD-1 $PRLD-1 $AAT-1 $NNE-1 $RBLX-1 $VTI-1 $IOVA-1 $EWY-1 $BMGL-1 $NBIS-1 $ORCU-1 $AA-1
October 29, 2026 at 8:46 PM
Vaccine Catalysts: $PCVX vs $MRK $PFE $SNY

Adult versus pediatric vaccines, trial endpoints and what immunogenicity can establish.

https://www.merlintrader.com/pcvx-mrk-pfe-sny-pneumococcal-vaccine-catalyst-comparison/
Vaccine Catalysts: $PCVX vs $MRK $PFE $SNY
Vaxcyte, Merck, Pfizer and Sanofi face different positions in adult and pediatric pneumococcal vaccines. We compare trial design, immunogenicity, market access, financing and catalyst timing, explaining why serotype count alone cannot rank the programs.
www.merlintrader.com
October 11, 2026 at 9:46 AM
#$PCVX: OPUS-1 met its primary endpoints, but supporting studies and manufacturing work remain. Our hub examines the comparator-level results, financing and expected H1 2028 BLA submission.
www.merlintrader.com/vaxcyte-stoc...
Vaxcyte $PCVX: VAX-31, OPUS And Vaccine Catalysts
Explore Vaxcyte's VAX-31 OPUS results, upcoming adult and infant studies, manufacturing, financing, competition and regulatory risks.
www.merlintrader.com
October 10, 2026 at 10:05 PM
What Moved This Week — Oct 5-9

Buyouts and Brazil: XP +49.9%, PCRX +44.0%, OPCH +37.2%, PTC +35.0%, PCVX +26.4%. Here's what moved this week and why.

$XP $PCRX $OPCH $PTC $PCVX #stocks #trading #stockmarket
https://confluencetradingtools.substack.com/p/what-moved-this-week-oct-5-9
October 10, 2026 at 1:13 PM
🚨 $PCVX
On October 6, 2026, Vaxcyte entered into an underwriting agreement with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters named therein , relating to the issuance and sale of 7,412,500 shares of Common Stock, at a price to the public of $64.00 per shar...
SEC Filing: PCVX
Click to view the official SEC document.
www.sec.gov
October 10, 2026 at 4:10 AM
🚨 $PCVX
On October 6, 2026, Vaxcyte entered into an underwriting agreement with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters named therein , relating to the issuance and sale of 7,412,500 shares of Common Stock, at a price to the public of $64.00 per shar...
SEC Filing: PCVX
Click to view the official SEC document.
www.sec.gov
October 9, 2026 at 8:43 PM
🚨 $PCVX
Cowan Elvia (SVP, Finance & CAO) sold 19,000 shares at an average price of $86.7400 per common share. (Date: 2026-10-05)
SEC Filing: PCVX
Click to view the official SEC document.
www.sec.gov
October 7, 2026 at 8:11 PM
🚨 $PCVX
Wassil Jim (EVP, Chief Scientific Ofc, COO) sold 18,000 shares at an average price of $86.7400 per common share. (Date: 2026-10-05)
SEC Filing: PCVX
Click to view the official SEC document.
www.sec.gov
October 7, 2026 at 8:12 PM